- Report
- July 2023
- 100 Pages
Global
From €4577EUR$4,750USD£3,937GBP
- Clinical Trials
- April 2024
- 80 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1927EUR$2,000USD£1,658GBP
- Report
- July 2023
- 69 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- March 2024
- 198 Pages
Global
From €3251EUR$3,374USD£2,797GBP
€3612EUR$3,749USD£3,107GBP
- Report
- May 2024
- 196 Pages
Global
From €4770EUR$4,950USD£4,103GBP
- Report
- November 2023
- 190 Pages
Global
From €4722EUR$4,900USD£4,061GBP
- Report
- April 2023
- 195 Pages
Global
From €9154EUR$9,500USD£7,874GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- January 2022
- 200 Pages
Global
From €7227EUR$7,500USD£6,217GBP
- Report
- January 2022
- 60 Pages
Global
From €3806EUR$3,950USD£3,274GBP
- Report
- January 2022
- 122 Pages
Global
From €4288EUR$4,450USD£3,688GBP
- Report
- May 2018
- 97 Pages
Global
From €2794EUR$2,900USD£2,404GBP
- Report
- August 2022
United States
From €1869EUR$1,940USD£1,608GBP
- Report
- August 2022
Global
From €761EUR$790USD£655GBP
- Report
- August 2022
Global
From €954EUR$990USD£821GBP
- Report
- August 2021
Global
From €3845EUR$3,990USD£3,307GBP
- Report
- August 2021
Europe
From €3295EUR$3,420USD£2,835GBP
- Report
- February 2021
Global
From €2852EUR$2,960USD£2,453GBP
- Clinical Trials
- March 2020
- 404 Pages
Global
From €2409EUR$2,500USD£2,072GBP
The Nephropathy Drug market is a subset of the larger Liver and Kidney Disorders Drugs market. It is composed of drugs used to treat nephropathy, a condition that affects the kidneys and can lead to kidney failure. These drugs are used to reduce inflammation, control blood pressure, and reduce the risk of further damage to the kidneys. They can also be used to treat other conditions such as hypertension, diabetes, and lupus.
The Nephropathy Drug market is highly competitive, with many companies offering a variety of treatments. These companies include major pharmaceutical companies such as Pfizer, Merck, and Novartis, as well as smaller companies such as Amgen, AstraZeneca, and Bristol-Myers Squibb. Additionally, there are many generic drug manufacturers that offer lower-cost alternatives to brand-name drugs. Show Less Read more